UPDATE ON CARMELINA, DPP4 INHIBITOR HAS VERY GOOD CV & RENAL OUTCOMES

Dear my friends and fellow Colleagues, Here is an update on CARMELINA RCT with Linagliptin, DPP4 Inhibitor vs Placebo. CARMELINA Randomized Trial Across all eGFR categories, in participants with type 2 diabetes and CKD and/or CVD there was no difference in risk for linagliptin versus placebo on CV and kidney events. Significant reductions in risk for albuminuria progression and HbA1c and no difference in AEs were observed. Hence Linagliptin has become the one and only OAD that can be used in any stage of Diabetic Kidney Disease apart from Insulin. Perkovic V et al, Diabetes Care 2020 May; 2020. dc200279 Regards and thanks, Dr Sepuri Krishna Mohan.

5 Likes

LikeAnswersShare

Informative and educative post. Thanks.

Valuable opinion
0

View 1 other reply

Yeah of all the gliptins linagliptin is effective& safe.with sglt2 inhibitors it is the combination of choice.thouhg the cost is bit high compared to other gliptins.

Valuable opinion
0

View 1 other reply

Cardiac and Renal safety is aditional advantage of linagliptin over other oha drugs.is always welcome

Valuable opinion
0

VERY USEFUL AND HELPFUL. UPDATE SIR.... NICELY ILLUSTRATED.....

Thank you doctor
0

Informative thanks

Valuable opinion
0

Very very useful

Valuable opinion
0

Cases that would interest you